{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-024036","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.752587+00:00","generated_at":"2026-05-17T13:17:22.695633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"bioAffinity Q2 2025 net loss $4.1M; CyPath Lung revenue up 62% H1","bullets":["Total revenue $1.3M in Q2 2025 vs $2.4M in Q2 2024, reflecting discontinuation of unprofitable pathology services.","CyPath Lung testing revenue grew 62% YTD to $323K; monthly tests set records in June and July.","Net loss $4.1M ($0.17/share) vs $2.1M ($0.19/share) in Q2 2024, increase driven by non-cash warrant remeasurement and offering costs.","Cash $0.8M at June 30, 2025; completed $3.25M public offering in May 2025 to bolster working capital.","Appointed Dr. Gordon Downie as CMO; expanded IP portfolio with patents in US, China, Canada, Australia."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-024036","json":"https://secwatch.observer/filing/0001641172-25-024036.json","markdown":"https://secwatch.observer/filing/0001641172-25-024036.md","text":"https://secwatch.observer/filing/0001641172-25-024036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/0001641172-25-024036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:17:22.695633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}